{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-011954","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.283305+00:00","generated_at":"2026-06-06T04:54:48.190235+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed appoints Netta Jagpal as CFO and Corporate Secretary effective Feb 20, 2024","bullets":["Netta Jagpal appointed CFO and Corporate Secretary effective Feb 20, 2024; replaces Jonathan Tegge as Interim CFO.","Annual base salary of CAD$325,000; eligible for annual discretionary bonus target of 40% of base salary.","Initial grant of 50,000 stock options subject to corporate approvals under the company's stock option plan.","Ms. Jagpal brings over 20 years of biotech finance experience from D-Wave Systems, Zymeworks, Angiotech, and Ernst & Young."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-011954","json":"https://secwatch.observer/filing/0001213900-24-011954.json","markdown":"https://secwatch.observer/filing/0001213900-24-011954.md","text":"https://secwatch.observer/filing/0001213900-24-011954.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/ea193307-8k_inmedpharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:54:48.190235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1902e4159d","claim":"Jonathan Tegge resigned as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..","evidence_excerpt":"Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on February 8, 2024, to serve as the Company’s Interim Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"ef2e2521ce","claim":"Netta Jagpal was appointed as Chief Financial Officer and Corporate Secretary at InMed Pharmaceuticals Inc..","evidence_excerpt":"appointed Ms. N. Netta “Neeta” Jagpal (“ Ms. Jagpal ”) ( aged 51 ) to serve, effective as of February 20, 2024 (the “ Effective Date ”), as Chief Financial Officer and Corporate Secretary of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Corporate Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}